ClinicalTrials.gg
CompletedNCT07107802Updated Nov 28, 2025

Phase 1 Single Ascending Dose Study With ATX101

A Phase 1 interventional study of ATX101 and Placebo in Healthy Participants, sponsored by Aurobac Therapeutics SAS. Completed at 1 site in Portugal. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Aurobac Therapeutics SAS · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective of this study is to assess the safety and tolerability of intravenously administered ATX101 in healthy adults following single ascending doses of ATX101. The pharmacokinetic profile of ATX101 and its metabolites will also be investigated.

Read the detailed description

This is a single-center, double-blinded, placebo-controlled, phase I, single ascending dose study in healthy participants. A maximum of three ATX101 dose levels are pre-planned to be investigated in three separate sequential cohorts. Each of these cohorts will consist of 8 healthy participants (6 participants randomized to ATX101 and 2 to placebo). The study will consist of:

  • a screening period, within 7 to 21 days before investigational product administration (Day -21 to Day -7),
  • a treatment period, including admission to confinement, 3-night confinement, and discharge from confinement.
  • a follow-up period, which includes two ambulatory follow-up visits (Day 4 and Day 7).

Total duration of study participation for each participant will be approximately 4 weeks.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

This is the only study on the registry with Aurobac Therapeutics SAS as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Free written prior to any procedure required by the study.
  2. Male or female participant ≥18 and ≤50 years-old, at the time of signing the informed consent.
  3. (BMI) between 18.5 and 29.9 kg/m2 and a minimum weight of 48 kg for women and 50 kg for men and maximum weight of 100 kg (inclusive).
  4. No diseases captured in medical history.
  5. No clinically relevant abnormalities at screening and admission.
  6. Negative test results for anti- 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), surface antigen (HBsAg), and anti- virus antibodies (anti-HCVAb).
  7. A female participant is either be of non-; or using an accepted method.

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to ATX101 or to ATX101 drug substance.
  2. Known /allergic reaction to the study drug substance or any of the .
  3. Known severe hypersensitivity reaction to any other drug.
  4. If woman, she is breast-feeding.
  5. Rest systolic blood pressure (SBP) \<90 mmHg or >140 mmHg.
  6. Rest diastolic blood pressure (DBP) \<50 mmHg/or >95 mmHg.
  7. Resting heart rate outside the range of 50 to 90 bpm, in the .
  8. Hematological and biochemistry parameters outside the normal range.
  9. Renal function outside normal range.
  10. Positive result in drugs-of-abuse or ethanol tests.
  11. If woman of (WOCBP), positive pregnancy test.
  12. Use of a depot injection or an implant of any drug within the previous 6 months.
  13. Average weekly alcohol consumption of >14 units for males and >7 units for females, within the previous 6 months.
  14. Average daily consumption of methylxanthines-containing beverages or food (e.g., coffee, tea, cola, sodas, chocolate) equivalent to >500 mg of methylxanthines, within the previous 6 months.
  15. Participation in any interventional clinical trial within the previous 2 months.
  16. Participation in more than 2 clinical trials within the previous 12 months.
  17. Blood donation or significant blood loss (≥450 mL) due to any reason or had plasmapheresis within the previous 2 months.
  18. Any other condition that the Investigator considers to render the participant unsuitable for the study.
  19. Any recent disease or condition or treatment that, according to the Investigator, would put the participant at undue risk due to study participation or occurred at a timeframe in which may interfere with the pharmacokinetics of study drug.
  20. Fever (≥38 ºC) in the previous week.
  21. Use of prescription or nonprescription medicinal products, vitamins, food supplements or herbal supplements (including St John's Wort) within 2 weeks prior to admission to the study, unless in the Investigator's opinion the medication does not interfere with the pharmacokinetics of study drug or compromise participant safety.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ATX101 - low dose

    Drug: ATX101

  • Experimental
    ATX101 - middle dose

    Drug: ATX101

  • Experimental
    ATX101 - high dose

    Drug: ATX101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugATX101

    Single intravenous dose

  • DrugPlacebo

    Single intravenous dose

06

What researchers measure

Primary outcomes

  1. Number and proportion of subjects with treatment-emergent adverse events (TEAEs). Occurrence of clinically relevant abnormalities on physical examination, safety laboratory tests, electrocardiogram parameters, and vital signs.

    Time frame: Up to Day 7

Secondary outcomes

  1. Maximum observed concentration (Cmax) of ATX101 in plasma

    Time frame: Up to Day 4

  2. Time of occurrence of the maximum observed concentration (tmax) of ATX101 in plasma

    Time frame: Up to Day 4

  3. Area under the concentration-time curve (AUC) of ATX101 in plasma from the start of infusion (t=0h) up to the end of infusion (AUC0-T)

    Time frame: Up to Day 4

  4. Partial area under the concentration-time curve (AUC) of ATX101 in plasma from the start of infusion (t=0h) up to 24 hours after the start of infusion (AUC0-24)

    Time frame: Up to 24 hours

  5. Area under the concentration-time curve (AUC) of ATX101 in plasma from the start of infusion (t=0h) up to the time of last measurable concentration (AUC0-t)

    Time frame: Up to Day 4

  6. Area under the concentration-time curve (AUC) of ATX101 in plasma from the start of infusion (t=0h) extrapolated to infinity (AUC0-∞)

    Time frame: Up to Day 4

  7. Residual area or percentage of extrapolated part of area under the concentration-time curve of ATX101 in plasma from the start of infusion (t=0h) extrapolated to infinity (%AUCextrap)

    Time frame: Up to Day 4

  8. Apparent terminal elimination rate constant (λz) of ATX101 in plasma

    Time frame: Up to Day 4

  9. Apparent terminal elimination half-life (t½) of ATX101 in plasma

    Time frame: Up to Day 4

  10. Apparent volume of distribution (VD) of ATX101 in plasma

    Time frame: Up to Day 4

  11. Apparent total body clearance (CL) of ATX101 in plasma

    Time frame: Up to Day 4

Other outcomes

  1. Maximum observed concentration (Cmax) of ATX101 metabolites in plasma

    Time frame: Up to Day 4

  2. Time of occurrence of the maximum observed concentration (tmax) of ATX101 metabolites in plasma

    Time frame: Up to Day 4

  3. Area under the concentration-time curve (AUC) of ATX101 metabolites in plasma from the start of infusion (t=0h) up to the end of infusion (AUC0-T)

    Time frame: Up to Day 4

  4. Partial area under the concentration-time curve (AUC) of ATX101 metabolites in plasma from the start of infusion (t=0h) up to 24 hours after the start of infusion (AUC0-24)

    Time frame: Up to 24 hours

  5. Area under the concentration-time curve (AUC) of ATX101 metabolites in plasma from the start of infusion (t=0h) up to the time of last measurable concentration (AUC0-t)

    Time frame: Up to Day 4

  6. Area under the concentration-time curve (AUC) of ATX101 metabolites in plasma from the start of infusion (t=0h) extrapolated to infinity (AUC0-∞)

    Time frame: Up to Day 4

  7. Residual area or percentage of extrapolated part of area under the concentration-time curve of ATX101 metabolites in plasma from the start of infusion (t=0h) extrapolated to infinity (%AUCextrap)

    Time frame: Up to Day 4

  8. Apparent terminal elimination rate constant (λz) of ATX101 metabolites in plasma

    Time frame: Up to Day 4

  9. Apparent terminal elimination half-life (t½) of ATX101 metabolites in plasma

    Time frame: Up to Day 4

  10. Metabolic ratios (MR) estimated for ATX101 metabolites in plasma

    Time frame: Up to Day 4

07

Study locations

1 site
  • BlueClinical Phase I
    Porto, 4250-449, Portugal
08

References and documents

Individual participant data

Plan to share: No — This is a healthy volunteer study being conducted to define the safety and pharmacokinetic profile of the tested drug. This study is not exploring the activity of our drug in the target indication population. As such, we do not believe there is utility for sharing deidentified IPD from this trial with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Oct 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 6, 2025
StartActual
Jul 19, 2025
Primary completionActual
Oct 24, 2025
CompletionActual
Oct 24, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07107802
Lead sponsor
Aurobac Therapeutics SAS
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Jul 19, 2025
Primary completion
Oct 24, 2025
Completion
Oct 24, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion